Key Highlights:
- India Glycols has completed its demerger into three separate entities, effective September 1, 2026, following NCLT approval. The businesses will now operate as India Glycols, IGL Spirits, and Ennature Bio Pharma, each focused on distinct segments.
- India Glycols will house chemicals, glycols, bio-glycols, specialty products and industrial gases, with ₹345 crore revenue in Q1 FY27. IGL Spirits will manage spirits and bio-fuels, reporting ₹694 crore, while Ennature Bio Pharma will house bio-pharma and bio-polymers, with ₹90 crore revenue.
- Shareholders will receive 1 IGL Spirits share for every India Glycols share and 1 Ennature Bio Pharma share for every 3 India Glycols shares held on September 2. The demerger aims to sharpen business focus, improve management oversight and enable more efficient capital allocation.
Implications:
The demerger splits India Glycols into three focused companies—chemicals/industrial gases (India Glycols), spirits/biofuels (IGL Spirits), and bio‑pharma/bio‑polymers (Ennature Bio Pharma)—so each can raise capital, manage operations, and be valued separately instead of as one bundled business. Shareholders will hold stakes in all three entities, which can lead to clearer market pricing for each segment and more efficient capital allocation as the spirits and high‑growth bio‑pharma arms are no longer hidden inside a larger chemicals group.
Source: India Glycols | Image: India Glycols
